-
Je něco špatně v tomto záznamu ?
Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state
T. Iida, S. Nii, H. Nishikawa, E. Kodama, H. Imai, M. Hashizume, R. Tadokoro, C. Sugisawa, T. Iizaka, F. Otsuka, S. Nagasaka
Status minimální Jazyk angličtina Země Japonsko
Typ dokumentu časopisecké články
Grantová podpora
NV19-09-00125
MZ0
CEP - Centrální evidence projektů
- Publikační typ
- časopisecké články MeSH
AIMS/INTRODUCTION: Glucagon plays a pivotal role in the development of hyperglycemia in diabetes mellitus. The purpose of this study was to investigate the hypothesis that hyperglucagonemia based on measurements of pancreas-specific glucagon is present in diabetic ketosis/ketoacidosis (DK/DKA) and hyperosmolar hyperglycemic state (HHS), and if so, to explore factors contributing to that hyperglucagonemia. MATERIALS AND METHODS: A total of 109 patients (92 with DK/DKA, and 17 with HHS) were investigated. Pancreas-specific glucagon levels were measured with a sandwich enzyme-linked immunosorbent assay at treatment initiation. The relationships of plasma glucagon levels, serum ketone bodies levels, and endogenous insulin secretion were assessed. The change in plasma glucagon levels after treatment was also assessed. RESULTS: The median plasma glucagon level was significantly higher in the HHS group (142.9 pg/mL) than in the DK/DKA group (63.6 pg/mL). In the DK/DKA group, the plasma glucagon level was positively correlated with the serum ketone bodies level (ρ = 0.55, P < 0.0001), but there was no correlation in the HHS group. In the DK/DKA group, a negative correlation was seen between the plasma glucagon level and the serum C-peptide immunoreactivity (CPR)/plasma glucose ratio in type 1 diabetes patients (n = 26) (ρ = - 0.67, P = 0.0002). In the HHS group, a positive correlation was seen between the plasma glucagon level and the serum CPR/plasma glucose ratio (ρ = 0.71, P = 0.0013). The plasma glucagon level was significantly lower after treatment in both the DK/DKA and HHS groups. CONCLUSIONS: Hyperglucagonemia was found in DK/DKA and HHS with pancreas-specific glucagon measurements. The results suggest that the causes of hyperglucagonemia differ in DK/DKA due to type 1 diabetes mellitus and HHS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-025-00852-8.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25025977
- 003
- CZ-PrNML
- 005
- 20251212152621.0
- 007
- ta
- 008
- 251210s2026 xr f 000 0|eng||
- 024 7_
- $a 10.1007/s13340-025-00852-8 $2 doi
- 035 __
- $a (PubMed)41292690
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Iida, Tatsuya $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan $1 https://orcid.org/0009000508210648
- 245 10
- $a Differential association of hyperglucagonemia with C-peptide levels in diabetic ketosis/ketoacidosis and hyperosmolar hyperglycemic state / $c T. Iida, S. Nii, H. Nishikawa, E. Kodama, H. Imai, M. Hashizume, R. Tadokoro, C. Sugisawa, T. Iizaka, F. Otsuka, S. Nagasaka
- 520 9_
- $a AIMS/INTRODUCTION: Glucagon plays a pivotal role in the development of hyperglycemia in diabetes mellitus. The purpose of this study was to investigate the hypothesis that hyperglucagonemia based on measurements of pancreas-specific glucagon is present in diabetic ketosis/ketoacidosis (DK/DKA) and hyperosmolar hyperglycemic state (HHS), and if so, to explore factors contributing to that hyperglucagonemia. MATERIALS AND METHODS: A total of 109 patients (92 with DK/DKA, and 17 with HHS) were investigated. Pancreas-specific glucagon levels were measured with a sandwich enzyme-linked immunosorbent assay at treatment initiation. The relationships of plasma glucagon levels, serum ketone bodies levels, and endogenous insulin secretion were assessed. The change in plasma glucagon levels after treatment was also assessed. RESULTS: The median plasma glucagon level was significantly higher in the HHS group (142.9 pg/mL) than in the DK/DKA group (63.6 pg/mL). In the DK/DKA group, the plasma glucagon level was positively correlated with the serum ketone bodies level (ρ = 0.55, P < 0.0001), but there was no correlation in the HHS group. In the DK/DKA group, a negative correlation was seen between the plasma glucagon level and the serum C-peptide immunoreactivity (CPR)/plasma glucose ratio in type 1 diabetes patients (n = 26) (ρ = - 0.67, P = 0.0002). In the HHS group, a positive correlation was seen between the plasma glucagon level and the serum CPR/plasma glucose ratio (ρ = 0.71, P = 0.0013). The plasma glucagon level was significantly lower after treatment in both the DK/DKA and HHS groups. CONCLUSIONS: Hyperglucagonemia was found in DK/DKA and HHS with pancreas-specific glucagon measurements. The results suggest that the causes of hyperglucagonemia differ in DK/DKA due to type 1 diabetes mellitus and HHS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-025-00852-8.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nii, Sayuri $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Nishikawa, Hiroto $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Kodama, Eriko $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Imai, Hideyuki $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Hashizume, Mai $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Tadokoro, Rie $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Sugisawa, Chiho $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Iizaka, Toru $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Otsuka, Fumiko $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 700 1_
- $a Nagasaka, Shoichiro $u Division of Diabetes, Metabolism, and Endocrinology, Showa Medical University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa 227-8501 Japan
- 773 0_
- $w def $t Diabetol Int $x 2190-1678 $g Roč. 17, č. 1 (2026), s. 1
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/41292690 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y -
- 990 __
- $a 20251210 $b ABA008
- 999 __
- $a min $b bmc $g 2446479 $s 1264175
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2026 $b 17 $c 1 $d 1 $e 20251123 $i 2190-1678 $m Diabetology international $n Diabetol Int $x def
- GRA __
- $a NV19-09-00125 $p MZ0
- LZP __
- $a AZV-2023-Pubmed-20251210